Avantax Advisory Services Inc. Raises Stake in Zoetis Inc. (NYSE:ZTS)

Avantax Advisory Services Inc. grew its stake in Zoetis Inc. (NYSE:ZTSFree Report) by 9.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,965 shares of the company’s stock after acquiring an additional 763 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Zoetis were worth $1,560,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ZTS. BOS Asset Management LLC grew its position in Zoetis by 3.2% in the 2nd quarter. BOS Asset Management LLC now owns 1,684 shares of the company’s stock valued at $290,000 after acquiring an additional 53 shares in the last quarter. Enterprise Financial Services Corp grew its position in Zoetis by 2.3% in the 1st quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock valued at $407,000 after acquiring an additional 55 shares in the last quarter. Catalyst Financial Partners LLC grew its position in Zoetis by 3.4% in the 2nd quarter. Catalyst Financial Partners LLC now owns 1,700 shares of the company’s stock valued at $293,000 after acquiring an additional 56 shares in the last quarter. CreativeOne Wealth LLC grew its position in Zoetis by 0.4% in the 2nd quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company’s stock valued at $2,210,000 after acquiring an additional 57 shares in the last quarter. Finally, MJP Associates Inc. ADV grew its position in Zoetis by 4.8% in the 3rd quarter. MJP Associates Inc. ADV now owns 1,275 shares of the company’s stock valued at $222,000 after acquiring an additional 58 shares in the last quarter. 89.47% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Up 0.5 %

Shares of ZTS stock opened at $197.15 on Thursday. The business’s fifty day moving average price is $192.06 and its 200 day moving average price is $182.95. Zoetis Inc. has a 1-year low of $151.03 and a 1-year high of $201.92. The firm has a market capitalization of $90.51 billion, a PE ratio of 40.07, a P/E/G ratio of 2.87 and a beta of 0.88. The company has a debt-to-equity ratio of 1.29, a current ratio of 3.87 and a quick ratio of 2.16.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Friday, January 19th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Thursday, January 18th. This is a positive change from Zoetis’s previous quarterly dividend of $0.38. Zoetis’s dividend payout ratio is currently 35.16%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ZTS shares. Stifel Nicolaus boosted their price objective on Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a research report on Friday, January 12th. Jefferies Financial Group reissued a “buy” rating and set a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, November 6th. The Goldman Sachs Group boosted their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 1st. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $223.78.

Get Our Latest Report on Zoetis

Insider Buying and Selling

In related news, CEO Kristin C. Peck sold 13,000 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $176.84, for a total transaction of $2,298,920.00. Following the transaction, the chief executive officer now owns 56,843 shares of the company’s stock, valued at $10,052,116.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Zoetis news, EVP Roxanne Lagano sold 2,500 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $200.00, for a total value of $500,000.00. Following the sale, the executive vice president now owns 19,415 shares of the company’s stock, valued at $3,883,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kristin C. Peck sold 13,000 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $176.84, for a total transaction of $2,298,920.00. Following the completion of the sale, the chief executive officer now directly owns 56,843 shares in the company, valued at approximately $10,052,116.12. The disclosure for this sale can be found here. Insiders have sold 17,346 shares of company stock valued at $3,139,405 over the last quarter. Company insiders own 0.12% of the company’s stock.

Zoetis Company Profile

(Free Report)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.